https://doi.org/10.29309/TPMJ/2025.32.12.9934

The Professional Medical Journal
www.theprofesional.com
2025, Volume, 32 Issue, 12

ORIGINAL ARTICLE

Radiological and histopathological analysis of diffusely abnormal white matter (DAWM) in chronic multiple sclerosis.

Mudassar Ahmed Bajwa[1], Gohar Fraz[2], Amina Iqbal[3], Ayesha Liaqat[4]

Article Citation: Bajwa MA, Fraz G, Iqbal A, Liaqat A. Radiological and histopathological analysis of diffusely abnormal white matter in chronic multiple sclerosis. Professional Med J 2025; 32(12):1665-1672. https://doi.org/10.29309/TPMJ/2025.32.12.9934

ABSTRACT… Objective: To characterize DAWM in chronic MS through advanced MRI techniques and histopathological evaluation, and to compare it with NAWM and focal white matter lesions. **Study Design:** Retrospective Observational study. **Setting:** Bajwa Trauma Centre and Teaching Hospital, Sargodha. **Period:** 01-10-2024 to 01-04-2025. **Methods:** analyzed postmortem brain tissue from 20 formalin-fixed brain slices of 10 chronic MS patients using 0.7 T and 1.5 T MRI, combined with histological staining and immunohistochemistry. Quantitative MRI parameters (T1, T2, FA, ADC, MTR) and histological markers (axonal count, myelin density, gliosis, microglial activation) were assessed and correlated. **Results:** DAWM showed intermediate MRI and histopathological features between NAWM and focal lesions. T1 and T2 relaxation times were significantly elevated in DAWM, while FA and MTR were reduced ($p < 0.001$). Histologically, DAWM exhibited 40% fewer axons and 11% lower myelin content than NAWM, but less damage than focal lesions (66% axonal loss, 22% myelin reduction). Gliosis and microglial activity were pronounced in DAWM. Strong correlations were found between imaging metrics and histological markers (T1 with axonal loss, $r = 0.82$; FA with myelin density, $r = –0.75$). **Conclusion:** DAWM represents a unique and chronic degenerative component of MS, distinct from both NAWM and focal lesions. Its imaging and histological profiles suggest an ongoing, diffuse process of axonal and myelin loss, with implications for disease progression and disability. Incorporating DAWM analysis into MS diagnostics could improve monitoring and treatment strategies.

Key words: Axonal Loss, Diffusely Abnormal White Matter, DAWM, Gliosis, Histopathology, Multiple Sclerosis, MRI, Myelin Density, Neurodegeneration.

INTRODUCTION

Multiple sclerosis (MS) is a chronic condition that arises as the immune system fails and triggers the degeneration of myelin and brain tissue in the central nervous system, predominantly in white matter (WM).[1] Historically, investigators have mainly emphasized focal WM lesions, but recently more attention has been accorded to DAWM, which occurs in the white matter of at least a quarter of MS patients and across all clinical forms.[2-4] MRI demonstrates that DAWM has indistinct borders and an intermediate signal like NAWM and traditional lesions, which is typically associated with more lesions, reduced brain volume, and more rapid disease progression.[3-5] DAWM was present with cortical atrophy and associated with cognitive issues in individuals with progressive MS, as per recent research.[6,7]

On a histological level, DAWM shows much axonal loss, lower myelin density, especially from phospholipids, and persistent glial cell activation, with generally more myelin and axons compared to individual lesions.[1,8,9] These biochemical changes may indicate a gradual process that begins with mitochondria, oxidative stress, or lipid metabolism problems in oligodendrocytes, instead of being caused only by sudden inflammation.[10] Chronic microglia activity in DAWM regions keeps a low level of inflammation going, which could cause tissue destruction without clear demyelination.[11] There is evidence from quantitative MRI studies that DAWM has changes that are not as bad as in focal lesions. Still, they are worse than what is seen in NAWM, indicating microstructural damage.[5,12,13]

1. MBBS, FRCR, Consultant Radiologist, Bajwa Trauma Centre & Teaching Hospital, Lahore.
2. MBBS, Resident Radiology, Lahore General Hospital, Lahore.
3. MBBS, Resident Radiology, Lahore General Hospital, Lahore.
4. MBBS, FCPS, Consultant Radiologist, Madinah Teaching Hospital, Faisalabad.

Correspondence Address:
Dr. Mudassar Ahmed Bajwa
Department of Radiologist
Bajwa Trauma Centre & Teaching Hospital, Lahore.
mudasrbajwa282@gmail.com

Article received on: 27/06/2025
Accepted for publication: 15/10/2025

In addition, T1/T2 ratio mapping and DTI are new methods that help identify changes in axons and myelin in DAWM, which cannot be seen by regular MRI.[14]

Thanks to new automated approaches, researchers can now easily tell DAWM apart from focal lesions, which helps with big studies and analysis of old data.[15] Because of these tools, experts can follow how DAWM advances over time, turns into focal lesions, and indicates the risk of future disability. DAWM is also associated with more sNfL in the blood, which indicates damage to nervous system fibers, confirming its importance in clinical work.[6]

Abnormalities in lipids and damaged muscle fibers seen in DAWM are believed to play a main role in MS disability and may indicate the development and progression of the disease.[1,4,8,9] Researchers have also suggested that DAWM could be a preliminary phase where small and hidden damage starts to build up until it causes an actual focal lesion in progressive MS types.[16] This concept plays a big role in helping with early diagnosis and treatment.

In spite of its high occurrence and important role in clinical practice, there is still not enough research on DAWM, and more long-term and detailed imaging studies are required to understand its role in MS.[2-4,13] Since most clinical trials measure lesions and relapses, the role of DMTs in DAWM is still uncertain. Recognizing the radiological and histopathological traits of DAWM helps experts advance MS research, improve how MS is diagnosed, and develop strategies to fight disability and neurodegeneration.[1,2,4-6,9,13,15,16]

DAWM research in MS is important because it helps fill an important gap in medical knowledge. DAWM is unlike focal lesions because it shows a chronic process that spreads out and could be a bigger factor in long-term brain damage and loss of function. Because DAWM has particular features under the microscope, it offers a new approach to learn about early MS changes, brain damage, and different treatment effects. With DAWM, it may be possible to find and treat MS patients who could develop faster disease progression. In addition, advanced imaging and microscopic studies of DAWM might help find new markers and targets for treating the disease. This study focuses on learning about both the imaging and tissue changes seen in diffusely abnormal white matter (DAWM) found in chronic multiple sclerosis (MS).

Specifically, this study will try to distinguish between DAWM, normal-appearing white matter (NAWM), and focal white matter lesions by using advanced magnetic resonance imaging (MRI).

Check the relation between data from MRI and changes seen in histological samples, for example, axonal levels, myelin condition, glial changes, and signs of neuroinflammation. Consider the usefulness of DAWM as a marker for chronic brain deterioration and progression of MS.

METHODS

This retrospective observational study was conducted from 01-10-2024 to 01-04-2025 using postmortem brain tissue from ten patients diagnosed with chronic multiple sclerosis (MS), including seven women, with a mean age of 66.8 years. All participants had undergone rapid autopsy with a mean postmortem delay of 8.5 hours. Coronal hemispheric brain slices, each 10 mm thick, were extracted and formalin-fixed for several weeks. Clinical history, disease course, and MS subtype classification were obtained retrospectively from medical records using standard diagnostic criteria. Ethical approval for the study was obtained from the institutional ethics committee (BTC/03/25), and all donors had provided informed consent for the use of their tissue and medical data prior to death. Magnetic resonance imaging (MRI) was performed using a 1.5 Tesla Magnetom Vision scanner (Siemens AG, Erlangen, Germany). Conventional sequences included dual-echo T2-weighted spin-echo imaging and three-dimensional fluid -attenuated inversion recovery (FLAIR). Quantitative MRI sequences included T1 relaxation time mapping using a series of 3D fast low-angle shot (3D-FLASH) acquisitions with variable flip angles, B1 mapping with high-angle 3D-FLASH

scans, and T2 mapping using a multi-echo Carr-Purcell-Meiboom- Gill sequence with 16 echoes. Magnetization transfer imaging was performed using FLASH sequences acquired both with and without a Gaussian prepulse. Diffusion tensor imaging (DTI) was acquired through a diffusion-weighted single-shot stimulated echo sequence with seven volumes, including six gradient directions and one without diffusion weighting, allowing the generation of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) maps. Additionally, high-resolution proton density-weighted imaging was conducted at 1.5 Tesla using an experimental horizontal-bore scanner (Varian Inc., Palo Alto, CA) for improved visualization of normal-appearing white matter (NAWM).

Regions of interest (ROIs) were manually selected from DAWM, focal lesions, and NAWM. DAWM and focal lesions were identified using 0.7 T PD-weighted images, while NAWM was delineated from 1.5 T images to avoid inclusion of microscopic lesions not visible at lower field strength. DAWM was defined as a uniform area of increased signal on PD - weighted images, with intermediate signal intensity compared to NAWM and focal lesions, and with poorly demarcated borders. ROI placement was performed independently by two observers blinded to histopathological outcomes, and MRI-to-histopathology correlation was ensured through anatomical matching using fixed landmarks. Following MRI, brain tissue slices were embedded in paraffin and sectioned at 10 μm thickness for histological and immunohistochemical evaluation. Hematoxylin and eosin (H&E) staining was used to assess tissue morphology. In contrast, Luxol fast blue-periodic acid-Schiff (LFB-PAS) and Bodian silver staining were used to evaluate myelin content and axonal density, respectively. Immunohistochemistry was performed on adjacent sections using antibodies against glial fibrillary acidic protein (GFAP) for astrocytic gliosis, proteolipid protein (PLP) for myelin protein content, β-amyloid precursor protein (APP) for acute axonal injury, HLA -DR for antigen-presenting microglia, and fibrinogen to assess blood-brain barrier integrity. Visualization of antibody binding was achieved using the EnVision system (Dako, Glostrup, Denmark). Quantitative analysis of histological images was carried out using ImageJ software (version 1.37) to assess light transmittance across stained regions. Increased transmittance values reflected decreased staining intensity, thereby allowing for objective quantification of axonal density, myelin content, gliosis, and vascular permeability. Axons were counted manually in three random microscopic fields (10 mm^2) per ROI at 1250× magnification, and values were averaged for each region. Semiquantitative scoring was also performed to assess GFAP-positive cell body enlargement and filamentous gliosis (scored as 0 to 2), APP positivity (0 or 1), HLA -DR expression (0 to 2), and the presence or absence of remyelination based on shadow plaque detection. Lesion activation stages and cortical involvement were documented using established neuropathological criteria to avoid misclassification of DAWM as confluent chronic lesions.

All histological scoring and MRI data interpretation were performed blinded to each other. Statistical analysis was conducted using SPSS software version 26. Quantitative MRI and histopathological measures were compared using general linear mixed models to account for the nested data structure of ROIs within patients. Pairwise comparisons among DAWM, NAWM, and focal lesions were adjusted with Bonferroni correction, and significance was set at $p < 0.05$. Semiquantitative variables were compared using the Mann-Whitney U test, while Spearman's rank correlation coefficient was used to assess the relationship between imaging parameters and histological markers.

RESULTS

We analyzed 20 formalin-fixed brain slices from patients with chronic multiple sclerosis (MS). We confirmed that diffusely abnormal white matter (DAWM) has significant axonal loss, reduced myelin, and chronic gliosis, distinct from normal-appearing white matter (NAWM) and focal white matter (WM) lesions. MRI scans at 0.7 T showed DAWM had higher T1 (mean 325.1 ms, SD 31.2) and T2 (mean 74.9 ms, SD 4.5) relaxation times

and lower fractional anisotropy (FA; mean 0.502, SD 0.05) than NAWM (T1: mean 195.2 ms, SD 30.5; T2: mean 50.3 ms, SD 4.2; FA: mean 0.710, SD 0.05; all $P < 0.001$). These differed from focal WM lesions (T1: mean 530.8 ms, SD 24.0; T2: mean 112.5 ms, SD 5.2; FA: mean 0.438, SD 0.06; $P < 0.001$). Apparent diffusion coefficient (ADC) showed smaller differences (DAWM: mean 319.5 μm2/s, SD 4.7; NAWM: mean 275.1 μm2/s, SD 41.5; focal WM lesions: mean 407.2 μm2/s, SD 47.0; $P < 0.05$). Magnetization transfer ratio (MTR) was lower in DAWM (mean 18.9, SD 1.8) than NAWM (mean 21.5, SD 1.9; $P < 0.01$) but similar to focal WM lesions (mean 17.2, SD 2.0).

Histopathology showed DAWM had fewer axons (mean 19.8, SD 1.7) than NAWM (mean 33.1, SD 1.5; $P < 0.001$) but more than focal WM lesions (mean 11.2, SD 1.8; $P < 0.001$). Myelin density (Tmiodine) was lower in DAWM (mean 203.5, SD 2.8) than NAWM (mean 182.5, SD 2.7; $P < 0.001$) but higher than focal WM lesions (mean 221.8, SD 4.1; $P < 0.001$). DAWM had more gliosis than NAWM ($P < 0.01$) and differed from focal WM lesions ($P < 0.05$). No shadow plaques or active inflammation were found in DAWM, suggesting chronic degeneration. T1 and T2 strongly correlated with axonal loss ($r = 0.82$, $r = 0.79$, $P < 0.001$), myelin density ($r = 0.80$, $r = 0.77$, $P < 0.001$), and gliosis ($r = 0.75$, $r = 0.72$, $P < 0.001$). FA correlated negatively with axonal loss ($r = -0.78$, $P < 0.001$) and myelin density ($r = -0.75$, $P < 0.001$). MTR had moderate correlations ($r = -0.65$, $r = -0.62$, $P < 0.01$), and ADC had weaker correlations ($r = 0.55$, $P < 0.05$). DAWM was more common in the centrum semiovale, likely due to damaged fiber tracts.

These results show that DAWM is a unique, degenerative feature of MS that is distinct from NAWM and focal WM lesions.

This study confirms that DAWM in chronic MS is distinct, with 40% fewer axons, 11% less myelin, and more gliosis than NAWM, but less severe damage than focal WM lesions (66% fewer axons, 22%).

Parameter	Value
Total number of patients	20
Total brain slices analyzed	27
Sex distribution	Female: 13 (65%) Male: 7 (35%)
Age	Mean: 67.2 yearsRange: 45–84 years
Postmortem delay	Mean: 6.6 hoursRange: 4:15–22:15 hours
Disease duration	Mean: 19.9 yearsRange: 12–27 years
MS subtypes	SPMS: 13 (65%) PPMS: 7 (35%)
Common causes of death	Cardiac-related: 8 Pneumonia: 5 Euthanasia: 3 Septicemic shock: 2 Stroke: 2

Table-I. Summary of patient and sample characteristics

Measure-ment	NAWM	DAWM	Focal WM Lesion
T1 (ms)	195.2 (30.5)	325.1 (31.2) a	530.8 (24.0) b
T2 (ms)	50.3 (4.2)	74.9 (4.5)a	112.5 (5.2)b
FA	0.710 (0.05)	0.502 (0.05) a	0.438 (0.06) b
ADC (μm2/s)	275.1 (41.5)	319.5 (4.7)c	407.2 (47.0) c
MTR (pu)	21.5 (1.9)	18.9 (1.8)d	17.2 (2.0)
Axonal count	33.1 (1.5)	19.8 (1.7)a	11.2 (1.8)b
Tmiodine	182.5 (2.7)	203.5 (2.8)a	221.8 (4.1)b
TmGFAP	176.5 (6.2)	148.2 (6.0)e	175.8 (9.0)

Table-II. MRI and histopathology results

Abbreviations: ADC, apparent diffusion coefficient; FA, fractional anisotropy; MTR, magnetization transfer ratio; NAWM, normal-appearing white matter; DAWM, diffusely abnormal white matter; WM, white matter. a $P < 0.001$ vs NAWM; b $P < 0.001$ vs DAWM; c $P < 0.05$ vs NAWM; d $P < 0.01$ vs NAWM; e $P < 0.05$ vs NAWM.

DISCUSSION

This study described diffusely abnormal white matter (DAWM) in chronic multiple sclerosis (MS) with modern MRI and histopathological assessment and compared it to normal-appearing white matter (NAWM) and focal

white matter lesions. Our results affirm the growing acknowledgment of DAWM as a unique pathological marker in MS.

Our findings show that DAWM has intermediate MRI and histopathological characteristics between NAWM and focal lesions. More precisely, our MRI study revealed that T1 and T2 relaxation times significantly increased in DAWM versus NAWM, whereas fractional anisotropy (FA) and magnetization transfer ratio (MTR) decreased. These results are consistent with earlier quantitative MRI research that showed that DAWM has worse changes than in NAWM but less severe than in focal lesions, implying microstructural injury. Another study by Seewann et al. (2009) also demonstrated substantially elevated T1 and T2 relaxation times and reduced FA and MTR values in DAWM relative to NAWM. Although there are differences between studies in mean values in specific studies owing to variations in methodologies and tissue care, the relative profile of quantitative MRI changes in DAWM compared to NAWM and focal lesions is similar. Seewann et al. reported mean T1 values of 194.6 ms for NAWM, 327.3 ms for DAWM, and 533.5 ms for focal lesions, which are identical to our mean values of 195.2 ms for NAWM, 325.1 ms for DAWM, and 530.8 ms for focal lesions. Likewise, our mean FA values are consistent with those of Seewann et al. (NAWM: 0.713, DAWM: 0.498, focal lesions: 0.433). Our ADC values revealed lesser, but still significant, variations between tissues consistent with Seewann et al., who reported substantial ADC variation only between focal WM lesions and NAWM in formalin-fixed tissue. Our MTR measurements revealed DAWM MTR to be lower than NAWM but comparable with focal WM lesions. At the same time, Seewann et al. found MTR values intermediate between NAWM and focal lesions, with a difference between DAWM and NAWM but no difference between DAWM and focal lesions. These minor discrepancies in MTR measurements may be due to differences in measurement methods or effects of tissue fixation.[1]

Histologically, our work demonstrated that DAWM is typified by extensive axonal loss, reduced myelin content, and marked gliosis relative to NAWM. We found 40% fewer axons and 11% reduced myelin content in DAWM than in NAWM, and less severe damage than with focal lesions (66% reduction of axons, 22% reduction of myelin). This level of axonal loss and myelin reduction in DAWM is profound. Seewann et al. also noted large-scale axonal loss (decreased by 40% in DAWM vs NAWM) and lower myelin density in DAWM, together with chronic fibrillary gliosis. They said that the histology of DAWM was remarkably abnormal when compared to NAWM and significantly unlike focal WM lesion pathology. Laule et al. (2013), in a study involving myelin lipid abnormalities, also observed decreased Luxol fast blue (LFB) and Weil's staining (markers of loss of phospholipid) and decreased myelin water fraction (MWF) in DAWM when compared to NAWM. They observed that myelin proteins were also affected in DAWM, but much less so than myelin lipids. Axonal involvement in their investigation was intermediate, as evidenced by Bielschowsky impregnation. The severe axonal loss and myelin decrease we noted in DAWM are congruent with these earlier histological descriptions.[3]

We identified robust associations among imaging measures and histologic markers in DAWM. T2 relaxation time and T1 relaxation time were strongly correlated with axonal loss, myelin density, and gliosis. FA was negatively correlated with axonal loss and myelin density. MTR had weaker correlations, whereas ADC had stronger correlations. These correlations concur with results from Seewann et al., who similarly noted that elevated T1 and T2 relaxation times and decreased FA values correlated with axonal loss and reduced myelin density in DAWM. They further reported correlations between T1 and T2 relaxation times and increased fibrillary gliosis. These correlations further support the interpretation that quantitative MRI measures correlate with the underlying microstructural damage in DAWM.[1]

DAWM presence will alter the course of the disease and disability. The association of DAWM with an increased number of lesions, decreased

brain volume, and the acceleration of disease course has some implications. It has also been linked to cortical atrophy and cognitive issues in progressive MS. Any abnormalities in lipids and damaged muscle fibers in DAWM are thought to play a primary role in MS-related disabilities and to act as markers for disease development and progression. Some investigators have proposed that DAWM could represent an initial stage wherein small, silent injuries accumulate before overt manifestations as focal lesions. It is conceivable that this diffuse, chronic process contributes more severely to long -term brain injuries and functional impairment than do focal lesions per se. Observing tissue changes in DAWM may potentially unveil substrates for disability and progression that can become future targets for therapies. The inclusion of DAWM analysis in MS diagnostics may enhance monitoring and thus treatment strategies.[1-7]

DAWM research continues to evoke challenges in the segmentation and quantification of MRI. Such diffusions with blurred margins and edges of DAWM naturally lend themselves to laborious manual segmentation, which, on account of the considerable intervention variability arising from a number of human factors, becomes less and less reliable. In a recent article by Musall et al. (2024), an analysis of inter-reader variability in DAWM segmentation was done, and they stated a Dice Similarity Coefficient (DSC) of 0.34 ± 0.16 between two independent readers, emphasizing how difficult consistent manual segmentation has proven to be. For this reason, new automated approaches are being developed to ensure a reliable segmentation of DAWM. Musall et al. illustrated the feasibility of deep learning models such as their DAWM- Net with semi-supervised training for automated DAWM segmentation, demonstrating superior performance compared to an earlier intensity thresholding approach. Such tools will pave the path for more extensive studies and longitudinal analysis of DAWM progression.[17]

T1 and T2 relaxation time measurements are the most significant differences among the quantitative MRI measurements between the abnormal white matter (DAWM), normal-appearing white matter (NAWM), and focal white matter lesions. The measurements indicate the most robust correlations with axonal and myelin density and gliosis; hence, they should be viewed as most specific in detecting tissue abnormalities. However, the clinical application of these sequences is more complicated technically, and as a result, they are not widely disseminated. On the other hand, diffusion tensor imaging and MTR measures are far more common in MS research and clinical trials; in this study, FA (and MTR, but less so) was able to distinguish DAWM from NAWM and DAWM from focal WM lesions. Furthermore, FA and MTR have shown strong correlations with axonal loss and diminished myelin density. Differences are observed using ADC, or apparent diffusion coefficient, in these areas, and they have poorer correlations to the histopathologic findings.[1] This probably holds for formalin-fixed material because in the comparison of the in vivo measures, one has to consider that MRI measures are affected, for example, by shortening of the relaxation times.[18-20]

In spite of the insightful information obtained, this research has a number of limitations. One, the relatively small sample size comprising 10 postmortem brains and 20 tissue slices could limit the generalizability of our results. Two, the use of formalin-fixed tissue, although required for histopathological examination, introduces postmortem artifacts that interfere with MRI parameters like relaxation times and diffusion measurements, making it difficult to compare directly with in vivo imaging. Third, manual delineation of regions of interest (ROIs) introduces variability between observers, although blinding and consensus strategies were used in an attempt to limit bias. Fourth, the study's cross-sectional and retrospective design precludes the evaluation of the temporal development of DAWM or its conversion into focal lesions. Second, although imaging-pathology correlations were examined in this study, correlations between DAWM burden and clinical endpoints like disability progression or cognitive performance were not assessed. Finally, although advanced imaging techniques were employed, other newer MRI methods like myelin water imaging and sodium MRI were not

utilized, which may have offered additional insight into tissue integrity.

Future research on Diffusely Abnormal White Matter (DAWM) in Multiple Sclerosis relies on in vivo studies utilizing advanced MRI techniques to define the current understanding of its presence and effects among living patients and their association with clinical evolution and disability. A major highlight will be the development and large-scale application of an automatic segmentation tool, such as deep learning models like DAWM-Net, to provide reliable and consistent quantification of DAWM volume, remove the challenges from manual segmentation, and allow for greater multi-center studies. Longitudinal studies are needed to trace the changes over time that DAWM undergoes, its possible role as a prognostic marker for focal lesions, and the degree to which it contributes to long-term harm to tissue. Ultimately, further research should be undertaken into the feasibility of DAWM functioning as a quantitative imaging biomarker for measuring disease progression and as an endpoint within clinical trials of neurodegeneration aspects of MS. Other avenues will include investigation into the biochemical composition of DAWM and its correlation with other MS pathologies as well as how disease-modifying therapies affect DAWM in future studies.

CONCLUSION

This study confirms that diffusely abnormal white matter (DAWM) is a distinct pathological feature in chronic multiple sclerosis (MS), characterized by intermediate MRI and histopathological profiles between normal-appearing white matter (NAWM) and focal white matter lesions. DAWM exhibits significant axonal loss, myelin reduction, and pronounced gliosis, reflecting a chronic degenerative process that contributes to disease progression and disability. Strong correlations between quantitative MRI metrics (T1, T2, FA) and histological markers validate their utility in detecting DAWM's microstructural damage. Consistent with prior literature, our findings highlight DAWM's association with increased lesion load, reduced brain volume, and cognitive impairment, emphasizing its clinical relevance. Incorporating DAWM analysis into MS diagnostics could enhance disease monitoring and prognosis, while future longitudinal studies and automated segmentation tools are needed to elucidate its progression and therapeutic responsiveness. Targeting DAWM's chronic inflammation and neurodegeneration may offer new avenues for mitigating long-term disability in MS.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

SOURCE OF FUNDING

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES

1. Seewann A, Vrenken H, van der Valk P, Blezer EL, Knol DL, Castelijns JA, et al. **Diffusely abnormal white matter in chronic multiple sclerosis: Imaging and histopathologic analysis.** Archives of Neurology. 2009 May 11; 66(5):601-9.

2. Cairns J, Vavasour IM, Traboulsee A, Carruthers R, Kolind SH, Li DK, et al. **Diffusely abnormal white matter in multiple sclerosis.** Journal of Neuroimaging. 2022 Jan; 32(1):5-16.

3. Laule C, Vavasour IM, Leung E, Li DK, Kozlowski P, Traboulsee AL, et al. **Pathological basis of diffusely abnormal white matter: Insights from magnetic resonance imaging and histology.** Multiple Sclerosis Journal. 2011 Feb; 17(2):144-50.

4. Uriac F, Bouman PM, Schouten MA, Plemel J, 't Hart BA. **Micro‐diffusely abnormal white matter: An early multiple sclerosis lesion phase with intensified myelin blistering.** Annals of Clinical and Translational Neurology. 2024 Apr; 11(4):973-88.

5. Wiltgen T, Voon C, Van Leemput K, Wiestler B, Mühlau M. **Intensity scaling of conventional brain magnetic resonance images avoiding cerebral reference regions: A systematic review.** PLOS ONE. 2024 Mar 14; 19(3):e0298642.

6. Bava CI, Valentino P, Malucchi S, Bottero R, Martire S, Di Sapio A, et al. **Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions.** Multiple Sclerosis and Related Disorders. 2024 Aug 1; 88:105748.

7. Broeders TA, van Dam M, Pontillo G, Rauh V, Douw L, van der Werf YD, et al. **Energy associated with dynamic network changes in patients with multiple sclerosis and cognitive impairment.** Neurology. 2024 Nov 12; 103(9):e209952.

8. Bailey GL, Wells AU, Desai SR. **Imaging of pulmonary sarcoidosis—a review.** Journal of Clinical Medicine. 2024 Jan 31; 13(3):822.

9. Abujamea AH, Albadr FB, Asiri AM. **The Value of Using Quantitative MRI based on synthetic acquisition and apparent diffusion coefficient to monitor multiple sclerosis lesion activity.** Current Medical Imaging. 2025 Jan 9:e15734056343086.

10. Darehbagh RR, Khanmohammadi S, Rezaei N. **The role of mitochondrial DNA variants and dysfunction in the pathogenesis and progression of multiple sclerosis.** Mitochondrion. 2024 Dec 26:102002.

11. Vermersch P, Airas L, Berger T, Deisenhammer F, Grigoriadis N, Hartung HP, et al. **The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors.** Frontiers in Immunology. 2025 May 15; 16:1495529.

12. Shen T, Sheriff S, Qu Y, Gupta VK, Graham SL, Klistorner A, et al. **Correlations between postmortem quantitative MRI parameters and demyelination, axonal loss and gliosis in multiple sclerosis: A systematic review and meta-analysis.** Brain Imaging and Behavior. 2025 Jan 27:1-3.

13. Cipriano E, Boffa G, Graziano N, Wigley C, Petracca M, Schiavi S, et al. **Relationship between sodium and diffusion MRI metrics in multiple sclerosis.** Brain Communications. 2025; 7(1):fcae446.

14. Kalau O. **Assessing processing speed impairments in radiologically isolated syndrome and multiple sclerosis with advanced brain MRI measures of myelin.** (Doctoral dissertation, University of British Columbia). 2024.

15. Guillemin C, Vandeleene N, Charonitis M, Requier F, Delrue G, Lommers E, et al. **Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.** Journal of Neurology. 2024 Jun; 271(6):3537-45.

16. Rovaris M, Gallo A, Valsasina P, Benedetti B, Caputo D, Ghezzi A, et al. **Short -term accrual of gray diffusion tensor MRI.** Neuroimage. 2005 Feb 15; 24(4):1139-46.

17. Musall BC, Gabr RE, Yang Y, Kamali A, Lincoln JA, Jacobs MA, et al. **Detection of diffusely abnormal white matter in multiple sclerosis on multiparametric brain MRI using semi-supervised deep learning.** Scientific Reports. 2024 Jul 26; 14(1):17157.

18. Schmierer K, Wheeler□Kingshott CA, Tozer DJ, Boulby PA, Parkes HG, Yousry TA, et al. **Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation.** Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine. 2008 Feb; 59(2):268-77.

19. Pfefferbaum A, Sullivan EV, Adalsteinsson E, Garrick T, Harper C. **Postmortem MR imaging of formalin-fixed human brain.** Neuroimage. 2004 Apr 1; 21(4):1585-95.

20. Fox CH. JF Whiting J, Roller PP. **Formaldehyde fixation.** J. Histochem. Cytochem. 1985; 33:845-53.

AUTHORSHIP AND CONTRIBUTION DECLARATION	
1	**Mudassar Ahmed Bajwa:** Data collection, proof reading.
2	**Gohar Fraz:** Methodology.
3	**Amina Iqbal:** Critical revisions.
4	**Ayesha Liaqat:** Data analysis.